{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T01:31:29Z","timestamp":1775611889758,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s10620-023-07826-3","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T05:02:36Z","timestamp":1678165356000},"page":"1118-1120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Besting the Biologics: Vancomycin Monotherapy for Ulcerative Colitis Management in Patients with Primary Sclerosing Cholangitis"],"prefix":"10.1007","volume":"68","author":[{"given":"Taqwa","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maia","family":"Kayal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Hashem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan C.","family":"Ungaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"7826_CR1","doi-asserted-by":"publisher","unstructured":"Cunha T, Vaziri H, Wu GY. Primary sclerosing cholangitis and inflammatory bowel disease: A review. J Clin Transl Hepatol. 2022;10(3):531\u2013542. doi. https:\/\/doi.org\/10.14218\/JCTH.2021.00344. Epub 2022 Jan 20. PMID: 35836773; PMCID: PMC9240248.","DOI":"10.14218\/JCTH.2021.00344"},{"issue":"1","key":"7826_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12328-020-01272-8","volume":"14","author":"AU Rahman","year":"2021","unstructured":"Rahman AU, Inayat F, Ali S et al. The role of oral vancomycin in inducing remission for biologic-experienced ulcerative colitis with concomitant primary sclerosing cholangitis and liver transplantation. Clin J Gastroenterol. 2021;14(1):159\u2013164. https:\/\/doi.org\/10.1007\/s12328-020-01272-8.","journal-title":"Clin J Gastroenterol."},{"key":"7826_CR3","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/hep.23294","volume":"51","author":"R Chapman","year":"2010","unstructured":"Chapman R, Fevery J, Kalloo A et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660\u2013678.","journal-title":"Hepatology."},{"issue":"5","key":"7826_CR4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jhep.2015.07.005","volume":"63","author":"R Ravikumar","year":"2015","unstructured":"Ravikumar R, Tsochatzis E, Jose S et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J. Hepatol. 2015;63(5):1139\u20131146. https:\/\/doi.org\/10.1016\/j.jhep.2015.07.005.","journal-title":"J Hepatol."},{"issue":"2","key":"7826_CR5","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/hep.23294","volume":"51","author":"R Chapman","year":"2010","unstructured":"Chapman R, Fevery J, Kalloo A et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51(2):660\u2013678.","journal-title":"Hepatology."},{"issue":"2","key":"7826_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/ecco-jcc\/jjv182","volume":"10","author":"M Meszaros","year":"2016","unstructured":"Meszaros M, Pageaux GP, Altwegg R. Management of ulcerative colitis using vedolizumab after liver transplantation for primary sclerosing cholangitis. J Crohns Colitis. 2016;10(2):236. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv182.","journal-title":"J Crohns Colitis."},{"issue":"9","key":"7826_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.17235\/reed.2017.5024\/2017","volume":"109","author":"RV Olmedo Mart\u00edn","year":"2017","unstructured":"Olmedo Mart\u00edn RV, Amo Trillo V, Gonz\u00e1lez Grande R et al. Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis. Rev Esp Enferm Dig. 2017;109(9):659\u2013662. https:\/\/doi.org\/10.17235\/reed.2017.5024\/2017.","journal-title":"Rev Esp Enferm Dig."},{"issue":"5","key":"7826_CR8","doi-asserted-by":"publisher","first-page":"e964","DOI":"10.1016\/j.cgh.2021.02.006","volume":"20","author":"K Quinn","year":"2022","unstructured":"Quinn K, Urquhart S, Janssens L et al. Primary sclerosing cholangitis-associated pouchitis: a distinct clinical phenotype. Clin Gastoenterol Hepatol. 2022;20(5):e964-973.","journal-title":"Clin Gastoenterol Hepatol."},{"key":"7826_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/35021219","volume":"406","author":"C Walsh","year":"2000","unstructured":"Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature. 2000;406:775\u2013781.","journal-title":"Nature."},{"key":"7826_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/ibd\/izz027","volume":"25","author":"A Dao","year":"2019","unstructured":"Dao A, Abidian M, Lestrange A et al. Oral vancomycin induces and maintains remission of ulcerative colitis in the subset of patients with associated primary sclerosing cholangitis. Inflamm Bowel Dis. 2019;25:90\u201391.","journal-title":"Inflamm Bowel Dis."},{"key":"7826_CR11","doi-asserted-by":"publisher","first-page":"S1480","DOI":"10.14309\/00000434-201710001-02727","volume":"112","author":"F Lodhi","year":"2017","unstructured":"Lodhi F, Mankongpaisarnrung C, Gerber D et al. Therapeutic effect of vancomycin in UC patients associated with PSC: case series. Am J Gastroenterol. 2017;112:S1480.","journal-title":"Am J Gastroenterol."},{"issue":"21","key":"7826_CR12","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.3748\/wjg.v26.i21.2768","volume":"26","author":"R Little","year":"2020","unstructured":"Little R, Wine E, Kamath B, et al. Gut microbiome in primary sclerosing cholangitis: a review. World J Gastroenterol. 2020;26(21):2768\u20132780.","journal-title":"World J Gastroenterol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-07826-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-023-07826-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-07826-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T07:37:39Z","timestamp":1681371459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-023-07826-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["7826"],"URL":"https:\/\/doi.org\/10.1007\/s10620-023-07826-3","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"assertion":[{"value":"16 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MK has served as a consultant for GoodRx and Abbvie. RCU has served as a consultant for AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda and has received research grants from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, and Pfizer. RCU supported by an NIH K23 Career Development Award (5K23DK111995).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}